

HOW TO PERFORM A TEST


Tests performed entirely in Italy
(two headquarters: Rome and Milan)



Sample collection



Sample shipment



Report receiving



The possibility to detect subjects at risk of developing a neoplasm related to hereditary mutations represents today the best method to reach an early diagnosis and to reduce mortality actualizing personalized surveillance programs.

Members of families with a high hereditary risk, and in particular those who have been directly affected by a neoplasm, can request genetic counselling and discuss their own genetic-clinical situation with the geneticist.


Next Generation Oncology Diagnostics

Test for the research of germline mutations predisposing to the development of tumors


Next Generation Oncology Diagnostics

Test for the study of circulating free tumor DNA in peripheral blood for the research of somatic mutations


Next Generation Oncology Diagnostics

Test for the molecular characterization of tumor tissues for the research of somatic mutations

WHY CHOOSE ONCONEXT™ BY GENOMA GROUP



Tests performed entirely in Italy
(two headquarters: Rome and Milan)




Rapid reporting:
15 working days



20 years of experience in genetics and molecular biology



Team of medical geneticists



Laboratories equipped with the most innovative technologies and advanced quality systems



Availability on all Italian territory

Onconext Risk TENG rev.00




Genetic tests for the study of the predisposition to the development of inherited tumors



PREVENTION
PERSONALIZED SUPERVISION
EARLY DIAGNOSIS

ONCONEXT RISK GENETIC TESTS ARE DIAGNOSTIC TESTS THAT ALLOW PERFORMING A MULTIPLE GENETIC ANALYSIS FOR THE DETECTION OF THE PREDISPOSITION TO HEREDITARY TUMORS.

The genes analyzed in **ONCONEXT RISK** tests codify for oncosuppressor proteins with the role of tumor suppressor genes. Patients carriers of germline mutations on these genes, having inherited a copy of the mutated gene, own a greater predisposition of developing, precociously and more easily than the general population, the tumor related to the mutated gene.



ONCONEXT RISK TESTS ARE ADVISABLE IN PERSONALIZED SURVEILLANCE PROGRAMS OF PATIENTS WITH PERSONAL OR FAMILY HISTORY OF:


- Tumors at an early age
- Multiple tumors in the same patient
- Suspected or proven predisposition to hereditary tumors

ONCONEXT™ RISK TESTS ARE AVAILABLE IN A TARGETED VERSION FOR DIFFERENT TYPES OF TUMOR



BREAST

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53



OVARIAN/UTERINE

BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53




COLON

APC, BMPRIA, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, PTEN, SMAD4, STK11, TP53



GASTRIC

APC, BMPRIA, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, STK11, SMAD4, TP53



PANCREAS

APC, ATM, BMPRIA, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53



MELANOMA

BAP1, BRCA2, CDK4, CDKN2A, MITF, PTEN, RB1, TP53



PROSTATE

ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53



CEREBRAL

AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, PRKARIA, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL



RENAL

BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL



PHEOCHROMOCYTOMA / PARANGANGLIOMA

FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL

ONCOSCREENING COMPLETE

GENE	Breast	Ovarian/Uterine	Colorectal	Gastric	Pancreas	Prostate	Melanoma	Cerebral	Renal	Pheochromocytoma/paraganglioma	Others
AIP								•			
ALK								•			
APC			•	•	•			•			
ATM	•				•	•					
BAP1							•		•		
BARD1	•										
BMPRIA			•	•	•						
BRCA1	•	•			•	•					
BRCA2	•	•			•	•	•				
BRIP1	•	•									
BUB1B										•	
CDC73											•
CDH1	•		•	•							
CDK4							•				
CDKN1B								•			
CDKN2A					•		•	•			
CEBPA										•	
CHEK2	•		•			•					
DICER1								•			
EGFR											•
EPCAM		•	•	•	•	•		•			
EXT1										•	
EXT2										•	
FH									•	•	
FLCN								•			
GALNT12											•
GATA2											•
GPC3											•
GREM1			•								•
HNF1A											•
HOXB13						•					
HRAS										•	
KIT										•	
MAX											•
MEN1								•		•	
MET									•		
MITF							•		•		
MLH1		•	•	•	•	•		•	•		
MRE11A	•										
MSH2		•	•	•	•	•		•	•		

GENE	Breast	Ovarian/Uterine	Colorectal	Gastric	Pancreas	Prostate	Melanoma	Cerebral	Renal	Pheochromocytoma/paraganglioma	Others
MSH6		•	•	•	•	•		•	•		
MUTYH	•		•								
NBN	•					•		•			
NF1	•							•		•	
NF2								•			
NSD1											•
PALB2	•	•			•	•					
PHOX2B								•			
PMS1											•
PMS2		•	•	•	•	•		•	•		
POLD1			•								
PRF1											•
PRKARIA								•			
PTCH1								•			
PTEN	•	•	•				•	•	•		
RAD50	•										
RAD51C	•	•									
RAD51D	•	•				•					
RB1							•				
RET											•
RHBDF2											•
RUNX1											•
SBDS											•
SDHA									•	•	
SDHAF2										•	
SDHB									•	•	
SDHC									•	•	
SDHD									•	•	
SMAD4			•	•							
SMARCA4								•			
SMARCB1								•			
SMARCE1								•			
STK11	•	•	•	•							
SUFU								•			
TMEM127											•
TP53	•	•	•	•	•	•	•	•	•		
TSC1								•	•		
TSC2								•	•		
VHL								•	•	•	
WT1											•



IT IS SUFFICIENT A PERIPHERAL BLOOD SAMPLE OF 3-5 ML